PI3K inhibitors as potential therapeutics for autoimmune disease

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1195-1199

  Ball, Jennifer ^a   Archer, Sophie ^a   Ward, Stephen ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

EVIDENCE BASED PRACTICE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; ENZYME INHIBITORS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS;

EID: 84906314487     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.04.002     Document Type: Review

References (35)

1. P.D. Arkwright et al. Autoimmunity in human primary immunodeficiency diseases Blood 99 2002 2694 2702
2. S.J. Walsh Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States Am. J. Public Health 90 2000 1463 1465
3. D. Van der Woude et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts Arthritis Rheum. 60 2009 2262 2271
4. P. Emery et al. A cost-effectiveness of biological therapeutic sequences for rheumatoid arthritis in the UK Value Health 12 2009 A439
5. B. Vanhaesebroeck et al. The emerging mechanisms of isoform-specific PI3K signalling Nat. Rev. Mol. Cell Biol. 11 2010 329 341
6. T. Bohnacker et al. PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells Sci. Signal. 2 2009 ra27
7. M.C. Schmid et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression Cancer Cell 19 2011 715 727
8. J. Guillermet-Guibert et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma Proc. Natl. Acad. Sci. U. S. A. 105 2008 8292 8297
9. M.D. Blunt, and S.G. Ward Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia Curr. Opin. Pharmacol. 12 2012 444 451
10. J.G. Foster et al. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies Pharmacol. Rev. 64 2012 1026 1054
11. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
12. E.H. Walker et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 6 2000 909 919
13. A. Berndt et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors Nat. Chem. Biol. 6 2010 117 124
14. B.J. Lannutti et al. CAL-101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
15. J. Hoellenriegel et al. The phosphoinositide 3-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood 118 2011 3603 3612
16. D.A. Fruman PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances Biochem. J. 442 2012 465 481
17. G. Bergamini et al. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation Nat. Chem. Biol. 8 2012 576 582
18. G.S. Firestein Evolving concepts of rheumatoid arthritis Nature 423 2003 356 361
19. M. Camps et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis Nat. Med. 11 2005 936 943
20. S. Hayer et al. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis FASEB J. 23 2009 4288 4298
21. B. Bartok et al. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis Am. J. Pathol. 180 2012 1906 1916
22. S. Toyama Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice Arthritis Res. Ther. 12 2010 R92
23. E.K. Wakeland et al. Genetic dissection of systemic lupus erythematosus Curr. Opin. Immunol. 11 1999 701 707
24. D.F. Barber et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus Nat. Med. 11 2005 933 935
25. K. Stylianou et al. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin Nephrol. Dial. Transplant. 26 2011 498 508
26. M.J. Maxwell et al. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease J. Autoimmun. 38 2012 381 391
27. A. Suárez-Fueyo et al. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death J. Immunol. 187 2011 2376 2385
28. M.A. Kleinschek et al. IL-25 regulates Th17 function in autoimmune inflammation J. Exp. Med. 204 2007 161 170
29. D.H. Rodrigues et al. Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis J. Neuroimmunol. 222 2010 90 94
30. S. Haylock-Jacobs et al. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation J. Autoimmun. 36 2011 278 287
31. C.A. Durand et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice Autoimmunity 46 2013 62 73
32. J. Azzi et al. The novel therapeutic effect of phosphoinositide 3-kinase-y inhibitor AS605240 in autoimmune diabetes Diabetes 61 2012 1509 1518
33. D.V. Serreze et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD, Ig mu null mice J. Exp. Med. 184 1996 2049 2053
34. J.P. Guo et al. IKBKE activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and PH domain to sustain malignant transformation J. Biol. Chem. 286 2011 37389 37398
35. N. Ilic et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E(e11 = 4E) axis Proc. Natl. Acad. Sci. U. S. A. 108 2011 E699 E708